Nithyakala P, Sathyaprabha G, Venila J
firstname.lastname@example.org , email@example.com
Nithyakala P1, Sathyaprabha G2, Venila J3
1KMCH College of Pharmacy, Kovai Estate, Kalapatti Road, Coimbatore - 641048, Tamil Nadu, India.
2Assistant Professor, Department of Pharmacy Practice, KMCH College of Pharmacy, Coimbatore.
3Statistician, KMCH College of Pharmacy, Coimbatore.
Volume - 14,
Issue - 3,
Year - 2021
Obesity is a serious and growing problem worldwide, contributes greatly to morbidity and mortality. This is a prospective – observational study of the weight loss on the efficacy of topiramate and Ispaghula in obese patients. To test the metabolic effects with hip and waist changes after topiramate and Ispaghula treatment of obesity patients for 6 months. Recent reports exposed the topiramate drug cause weight reduction in different patients in the test group. The drug was more effective in the topiramate group than in the Ispaghula group. Methods: Patient information leaflets were distributed for obese patients. The Patient’s weight, height, and BMI have recorded in 2 weeks intervals. The Study was conducted between 0 to 6 months. The final dose of topiramate 25mg to 50mg/per day and Ispaghula 1.2gm to 3.6gm/per day varied from and respectively. The obesity patients are advised to modify their lifestyle along with diet control and specifically, topiramate was given to group 2 patients. Results: Topiramate was effective in reducing the weight in 29 out of the 30 patients. Among the study population the greater number of the population, comes under the age group of 28-37years (10) - 33.3% in group 1 and it’s similar in case of group 2 where a higher number of population is under the age group of 28-37 years (10)-33.3%. The mean BMI of the group 1 patient during first visit was found to be 33.68 which were reduced to 31.13 during the sixth month. Similarly in the group 2 patients the mean BMI during the first visit was 32.81 which got reduced drastically to 21.37. Conclusion: In our study indicates the rapid emerge of obesity and its associated health issues in urban society peoples because of their improper lifestyle. The result of our study suggests that the topiramate drug is effective in the treatment of the obese patient with a good sum of weight loss. Topiramate could be considered in the treatment of obesity patients. When comparing the average BMI results of Ispaghula and tropiramate, the results were observed that the topiramate drug is more effective to reducing weight in Group 2(test) patients.
Cite this article:
Nithyakala P, Sathyaprabha G, Venila J. Study on Efficacy of Topiramate: Impact on weight Loss in Obese patients. Research J. Pharm. and Tech 2021; 14(3):1565-1570. doi: 10.5958/0974-360X.2021.00276.6
Nithyakala P, Sathyaprabha G, Venila J. Study on Efficacy of Topiramate: Impact on weight Loss in Obese patients. Research J. Pharm. and Tech 2021; 14(3):1565-1570. doi: 10.5958/0974-360X.2021.00276.6 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-3-66
1. Bridget Paravattil et al. Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes research and clinical practice. 2016; 114:9-14
2. Rashid Kazerooni. Topiramate –associated weight loss in a veteran population. Military medicine. 2016; 181:3:283
3. Thrinitha et al. An observational study approach the safety and efficacy of phentermine, topiramate in obese patients. International Journal of Pharmacy and Biological Sciences .2018; 3: 289-298
4. Hirotaka Iwaki et al. Topiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy. Epilepsy and Behavior.2018; 87-91
5. Rohan Khera et al. Effects of weight-loss medications on cardio metabolic risk profiles: a systematic review and network meta-analysis. Gastroenterology. 2018; 154:1309–1319
6. Fabricatore et al. Intentional weight loss and change in symptoms of depression: a systematic review and meta-analysis. Int J Obes (Lond). 2011; 35: 1363 -76.
7. Jovanovski et al. "Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials". The American Journal of Clinical Nutrition. 108 (5): 922–932.
8. Fischer et al. The gel-forming polysaccharide of psyllium husk (Plantago ovata Forsk). Carbohydr Res. 2004 Aug 2; 339(11): 2009–17.
9. Rock et al. Effects of diet composition on weight loss, metabolic factors, and biomarkers in a 1-year weight loss intervention in obese women examined by baseline insulin resistance status. Metabolism 2016; 65(11):1605–13.
10. Nelson SM, Fleming R. Obesity and reproduction: impact and interventions. Curr Opin Obstet Gynecol 2007; 19: 384-9.
11. Coll. J. L et al. Prevalence and Related Risk Factors of Overweight and Obesity among the Adult Population in the Balearic Islands, a Mediterranean Region. Obes Facts. 2015; 8(3): 220-33
12. Suyog Jain et al. Evaluation of efficacy and safety of orlistat in obese patients. Indian Journal of Endocrinology and Metabolism. 2011; 15: 99-104.
13. Amudha Poobalan et al. Obesity Among Young Adults in Developing Countries: A Systematic Overview. Curr Obes Rep 2016; 5:2–13
14. Julio Rosenstock et al. A Randomized, Double-Blind, Placebo-Controlled, multicenter Study to Assess the Efficacy and Safety of Topiramate Controlled Release in the Treatment of Obese Type 2 Diabetic Patients. Diabetes Care. 2007; 30: 1480-1486
15. Kramer et al. Efficacy and safety of topiramate on weight loss: a meta analysis of randomized controlled trials. International association for the study of obesity. 2010; 12: 338-347
16. Eliasson et al. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. International Journal of Obesity 2007; 31: 1140–1147.